Efficacy of oral versus vaginal progestogens for early pregnancy maintenance in women with recurrent miscarriages: a randomized controlled trial
Article Sidebar
Main Article Content
Abstract
OBJECTIVE: To compare the effectiveness of oral and vaginal progestogens in the maintenance of early pregnancy in women with recurrent miscarriages.
METHODS: This randomized controlled trial was conducted at Lady Reading Hospital, Peshawar, Pakistan, from April to September 2021. Pregnant women aged 16–40 years with a history of at least three recurrent miscarriages presenting at or before 7 weeks of gestation were enrolled. A total of 108 patients were randomly assigned to two groups: Group A received oral progestogens (10 mg twice daily), and Group B received vaginal progestogens (200 mg twice daily). Treatment lasted for 12 weeks, with successful outcomes defined as no vaginal bleeding and pregnancy continuing beyond 12 weeks. Data analysis was conducted using SPSS-20 software.
RESULTS: The mean age of patients was 29 ± 3.88 years in Group A and 27 ± 3.12 years in Group B. Oral progestogens (Group A) were effective in 48 (88.9%) patients, whereas vaginal progestogens (Group B) were effective in 36 (66.7%) patients (p=0.03). Oral progestogens showed significantly greater efficacy compared to vaginal progestogens in individuals aged 20-30 years (p=0.04) and those with fewer than four previous miscarriages (p=0.03). However, there was no significant difference in efficacy between the two groups for participants aged 31-40 years or those with 4 or more previous miscarriages.
CONCLUSION: Oral progestogens are more effective than vaginal progestogens in preventing recurrent miscarriages, especially in participants aged 20–30 years and with fewer than 4 previous miscarriages. More research needed to validate and explore underlying mechanisms.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Work published in KMUJ is licensed under a
Creative Commons Attribution 4.0 License
Authors are permitted and encouraged to post their work online
(e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
Regan L, Rai R, Saravelos S, Li TC; Royal College of Obstetricians and Gynaecologists. Recurrent Miscarriage Green-top Guideline No. 17. Br J Obstetrics Gynecol 2023 Nov;130(12):e9-e39. https://doi.org/10.1111/1471-0528.17515.
Linehan LA, San Lazaro Campillo I, Hennessy M, Flannery C, O’Donoghue K. Reproductive outcomes following recurrent first-trimester miscarriage: a retrospective cohort study. Hum Reprod Open 2022;2022(4):hoac045.
Navya G, Raghuwanshi N, Chavan R. Clinico-epidemiological profile and evidence based management of recurrent miscarriages in a tertiary care centre. Int J Adv Res 2023; 11(05):613-627. https://www.journalijar.com/article/44810/
Ali S, Majid S, Ali NM, Taing S, El-Serehy HA, Al-Misned FA. Evaluation of etiology and pregnancy outcome in recurrent miscarriage patients. Saudi J Biol Sci 2020;27(10):2809-17. https://doi.org/10.1016/j.sjbs.2020.06.049
Tsonis O, Balogun S, Adjei JO, Mogekwu O, Iliodromiti S. Management of recurrent miscarriages: an overview of current evidence. Curr Opin Obstet Gynecol 2021;33(5):370-7. https://doi.org/10.1097/GCO.0000000000000735.
Patki A., Chauhan N. An epidemiology study to determine the prevalence and risk factors associated with recurrent spontaneous miscarriage in India. J Obstet Gynecol India 66 (2016), pp. 310-315, https://doi.org/10.1007/s13224-015-0682-0
Barnhart KT, Katz I, Hummel A, Gracia CR. Presumed diagnosis of ectopic pregnancy. Obstet Gynecol 2002;100(3):505-10. https://doi.org/10.1016/S0029-7844(02)02142-7
Arab H, Alharbi AJ, Oraif A, Sagr E, Al Madani H, Abduljabbar H, et al. The role of progestogens in threatened and idiopathic recurrent miscarriage. Int J Womens Health 2019;11:589-96. https://doi.org/10.2147/IJWH.S224159
Condous G, Kirk E, Lu C. There is no role for uterine curettage in the contemporary diagnostic workup of women with a pregnancy of unknown location. Hum Reprod 2006;21(10):2706-10. https://doi.org/10.1093/humrep/del223
Nelson DB, Hanlon AL, Wu G, Liu C, Fredricks DN. First trimester levels of BV-associated bacteria and risk of miscarriage among women early in pregnancy. Matern Child Health J 2015;19(12):2682-7. https://doi.org/10.1007/s10995-015-1790-2
Giakoumelou S, Wheelhouse N, Cuschieri K, Entrican G, Howie SE, Horne AW. The role of infection in miscarriage. Hum Reprod Update 2016;22(1):116‐33. https://doi.org/10.1093/humupd/dmv041
Thangaratinam S, Tan A, Knox E. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ 2011;342:d2616. https://doi.org/10.1136/bmj.d2616
Barbosa MWP, Valadares NPB, Barbosa ACP, Amaral AS, Iglesias JR, Nastri CO, et al. Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis. JBRA Assist Reprod 2018;22(2):148‐56. https://doi.org/10.5935/1518-0557.20180018
Maconochie N, Doyle P, Prior S, Simmons R. Risk factors for first trimester miscarriage results from a UK-population-based case-control study. Br J Obstet Gynecol 2007;114(2):170-86. https://doi.org/10.1111/j.1471-0528.2006.01193.x
Lucovnik M, Kuon RJ, Chambliss LR, Maner WL, Shi SQ, Shi L, et al. Progestin treatment for the prevention of preterm birth. Acta Obstet Gynecol Scan 2011;90(10):1057‐69. https://doi.org/10.1111/j.1600-0412.2011.01178.x
Abrar S, Abrar T, Tahir M, Sayyed E. Efficacy of oral with vaginal progesterone in the treatment of threatened miscarriage in first trimester. Pak J Med Sci 2017;25(4):407-10. https://doi.org/10.12669/pjms.37.3.3700
Di Renzo GC, Giardina, I, Clerici G, Brillo E, Gerli S. Progesterone in normal and pathological pregnancy. Hor Mol Bio Clin Investig 2016;27(1):35-48. https://doi.org/10.1515/hmbci-2016-0038
Schumacher A, Costa SD, Zenclussen AC. Endocrine factors modulating immune responses in pregnancy. Front Immunol 2014;5:196. https://doi.org/10.3389/fimmu.2014.00196
Yassaee F, Shekarriz-Foumani R, Afsari S, Fallahian M. The effect of progesterone suppositories on threatened abortion: A randomized clinical trial. J Reprod Infertil 2014;15(3):147.
Dante G, Vaccaro V, Facchinetti F. Use of progestagens during early pregnancy. Facts Views Vis Obgyn 2013;5(1):66-71.
Ghosh S, Chattopadhyay R, Goswami S, Chaudhury K, Chakravarty B, Ganesh A. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. J Obstet Gynaecol Res 2014;40(7):1871‐6. https://doi.org/10.1111/jog.12456
Wang XX, Luo Q, Bai WP. Efficacy of progesterone on threatened miscarriage: difference in drug types. J Obstet Gynaecol Res 2019;45(4):794-802. https://doi.org/10.1111/jog.13909
Wahabi H, Fayed A, Esmaeil A, Al-Zeidan A. Progestogen for treating threatened miscarriage. The Cochrane Database of Systematic Reviews 2011;12:CD005943.005943. https://doi.org/10.1002/14651858.CD005943.pub5
El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas 2009;65(1):S43-6. https://doi.org/10.1016/j.maturitas.2009.11.013
Lee HJ, Park TC, Kim JH, Norwitz E, Lee B. The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Meta-Analysis. Biomed Res Int 2017;3616875. https://doi.org/10.1155/2017/3616875
Kasap E, Karaarslan S, Gene M, Gur EB, Sahin N, Guclu S. The role of cytokines in first trimester pregnancy losses with fetal chromosomal anomaly. Ginekol Pol 2015;86(11):827-32.